Home | Welcome to Contract Pharma   
Last Updated Tuesday, October 21 2014
Print

Financial Report: Teva



Published May 1, 2014
Teva
 
1Q Revenues: $5.0 billion (+2%)
 
1Q Earnings: $740 million  (+18%)
 
Comments:
Generic revenues were $2.4 billion (including API sales of $179 million), up 3% in the quarter. Specialty medicine revenues were $2.1 billion, up 3%, driven by CNS and oncology products, partially offset by lower revenues of other specialty medicines. Copaxone sales were up 1% to $1.1 billion. Azilect sales were up 23% to $114 million. Nuvigil sales were $101 million, up 22%. Provigil sales were down 13% to $21 million. Treanda sales were up 5% to $180 million. OTC revenues were $269 million, down 12%, primarily due to lower sales in Eastern Europe.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On